Hence, we undertook a meta‐analysis to explore the effects of SGLT2 inhibitors on erythropoiesis parameters and the associated beneficial cardiorenal protection effects in T2DM patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.